Curative Biotechnology Inc — Cyborg Score 3/10

Weak
Pharmaceuticals / Rare Disease Biotech / Ophthalmic Therapeutics

Strategic Profile

Curative's lead program centers on a topical metformin eye drop formulation for treating age-related macular degeneration (AMD), geographical atrophy, and other degenerative eye conditions. The company also maintains programs in infectious disease and neuro-oncology, with recent efforts toward OTCQB uplisting and capital structure strengthening through strategic initiatives.

Cyborg Score Rationale

As a micro-cap development-stage biomedical company trading at $0.01 per share with an $8.81 million market cap, Curative faces significant execution risk. Recent reverse stock split (1-for-150) and need for capital raises indicate financial constraints. Limited revenue-generating operations and dependence on successful clinical trials create substantial uncertainty.

Top Insights

  • Exclusive NIH license for metformin-based eye drop formulation addresses unmet needs in AMD and geographic atrophy
  • Successfully completed IND-enabling toxicology studies as of January 2023, positioning for IND application submission
  • Recent 1-for-150 reverse stock split (March 2026) and capital strengthening efforts suggest transition toward OTCQB uplisting
  • Multi-program pipeline across degenerative eye disease, infectious disease, and neuro-oncology provides diversification but strains limited resources

Named Competitors

  • Ionis Pharmaceuticals — Develops RNA therapeutics for retinal diseases including geographic atrophy
  • Genentech/Roche — Pursuing complement inhibition and anti-VEGF approaches for AMD treatment
  • Apellis Pharmaceuticals — Complement-targeted therapies for age-related macular degeneration

Recent Developments

  • (March 2026) Announced 1-for-150 reverse stock split and strategic progress toward OTCQB uplisting
  • (March 2026) Capital structure strengthening initiatives and engagement of strategic advisors
  • (January 2023) Completed IND-enabling tolerance and toxicology studies for metformin eye drop formulation

Open the full interactive Curative Biotechnology Inc report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →